Preventing Recurrent Bacterial Vaginosis by Treating Male Sexual Partners with Combined Oral and Topical Antibiotics
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 21st, 2025
|
Bacterial vaginosis is marked by a disruption of the normal vaginal microbiota, and previous research suggests that the penile microbiome of a male partner may predict the occurrence of bacterial vaginosis in the female partner. Funded by the National Health and Medical Research Council of Australia, a study was conducted to evaluate whether treating the male partner could help prevent recurrence in women.
The clinical study enrolled 159 heterosexual, monogamous couples in which the female partner had been diagnosed with bacterial vaginosis. Approximately 30% of the women used an intrauterine device for contraception, while less than 5% consistently used condoms. On average, the female participants had experienced three prior episodes of bacterial vaginosis. All female participants received standard first-line antimicrobial treatment—either oral metronidazole, intravaginal clindamycin, or intravaginal metronidazole. Half of the couples were randomized so that the male partner received a 7-day treatment consisting of 400 mg of metronidazole twice daily along with 2% clindamycin applied topically twice daily, while the remaining male partners did not receive placebo topical treatment because of concerns that a placebo cream might affect the penile microbiome.
Following the 12-week post-treatment follow-up, researchers found that treating male partners with both oral and topical antimicrobial agents significantly reduced the risk of recurrent bacterial vaginosis in female partners by 63%. The study also highlighted that previous research on male partner interventions was limited due to small sample sizes or ineffective antibiotic administration methods. Furthermore, adherence to treatment was significantly higher among men using metronidazole cream compared to those using clindamycin, a factor that contributed to the observed preventive effectiveness.
The clinical study enrolled 159 heterosexual, monogamous couples in which the female partner had been diagnosed with bacterial vaginosis. Approximately 30% of the women used an intrauterine device for contraception, while less than 5% consistently used condoms. On average, the female participants had experienced three prior episodes of bacterial vaginosis. All female participants received standard first-line antimicrobial treatment—either oral metronidazole, intravaginal clindamycin, or intravaginal metronidazole. Half of the couples were randomized so that the male partner received a 7-day treatment consisting of 400 mg of metronidazole twice daily along with 2% clindamycin applied topically twice daily, while the remaining male partners did not receive placebo topical treatment because of concerns that a placebo cream might affect the penile microbiome.
Following the 12-week post-treatment follow-up, researchers found that treating male partners with both oral and topical antimicrobial agents significantly reduced the risk of recurrent bacterial vaginosis in female partners by 63%. The study also highlighted that previous research on male partner interventions was limited due to small sample sizes or ineffective antibiotic administration methods. Furthermore, adherence to treatment was significantly higher among men using metronidazole cream compared to those using clindamycin, a factor that contributed to the observed preventive effectiveness.